Background {#Sec1}
==========

One of the characteristic epigenetic hallmarks of cancer is aberrant DNA methylation, the presence of a 5′-methyl group on cytosine bases in the context of CpG dinucleotides. Across numerous malignancies, both aberrant global hypomethylation and promoter hypermethylation of numerous loci have been reported to promote carcinogenesis by increasing genomic instability and by altering gene expression \[[@CR1]--[@CR4]\]. In cancer, epimutations including promoter DNA hypermethylation, are known to occur more frequently than genomic abnormalities \[[@CR5]\], and thus form an attractive target for biomarker discovery. Furthermore, the identification of CpG island methylator phenotypes (CIMP) in glioblastomas and colorectal carcinomas have provided proof-of-principle that methylation profiling could provide a means to identify subsets of epigenetically and genetically distinct diseases that are informative for patient outcome \[[@CR6], [@CR7]\].

In head and neck squamous cell carcinomas (HNSCC), both locus-specific methylation and methylation profiles identified with a variety of methods have been reported to be both biologically and prognostically significant \[[@CR8]--[@CR14]\]. However, the clinical utility of these reported hypermethylated loci has been limited by the use of heterogeneous HNSCC cohorts and is further complicated by the diversity of non-reproduced loci identified by these reports \[[@CR15]\]. Little is understood about the significance of methylation according to individual head and neck subsites, including oral tongue squamous cell carcinomas (OTSCC), which have the worst overall survival for early-stage disease \[[@CR16], [@CR17]\]. Beyond the subset of human papillomavirus-induced oropharyngeal carcinomas \[[@CR18], [@CR19]\], no clinically impacting molecular markers are utilised routinely for all other head and neck cancers. Therefore, the burden of need exists for the identification of clinically relevant biomarkers to assist with improved disease stratification and treatment allocation.

The Illumina HumanMethylation450K (HM450K) array provides a quantitative high throughput platform for the genome-scale assessment of methylation \[[@CR20]\]. This array interrogates a total of 482,421 CpG sites located predominantly in promoter regions, but crucially also includes coverage of CpG island (CGI) shores which contain the most differentially methylated regions in cancer \[[@CR2], [@CR21]\]. Thus, in comparison to a candidate gene approach, CpG sites can be simultaneously interrogated for the purpose of identifying potentially informative specific loci or methylation signatures.

We sought to identify a clinically relevant methylation profile in a large cohort of comprehensively annotated OTSCC with the HM450K array. In addition, methylation data from the heterogeneous cohort of HNSCC samples generated by The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>) were analysed, which included a similar sized subset of OTSCC.

Results {#Sec2}
=======

Patient samples {#Sec3}
---------------

The OTSCC patient cohort from the Peter MacCallum Cancer Centre has been previously described (Table [1](#Tab1){ref-type="table"}) \[[@CR15], [@CR22]\]. Briefly, the cohort consisted of patients with invasive OTSCC, with comprehensive clinicopathological details and pre-treatment archival specimen blocks. For this study, 109/131 samples had sufficient DNA for analysis on the HM450K array.Table 1Patient and tumour characteristics \[[@CR22]\]NumberPercentGender Female4837 Male8363Age at diagnosis (in years) Mean57.8 Standard deviation15.1 Median60 Range21--93 \<40 years1511 40--49 years2620 50--59 years2418 60--69 years3224 70--79 years2721 80+ years75Stage 13728 23728 31511 44232T category 14333 25139 31411 42318N category 08363 11411 23426Smoking history No/never3930 Yes8867 Unknown4Alcohol \>20 g/day No/never/social8162 Past or current4635 Unknown4ECOG performance status 07658 14031 297 343 Unknown2

Level 1 raw IDAT files were downloaded from the TCGA data portal (<https://tcga-data.nci.nih.gov>) on 24 June, 2013, and the clinical annotation was downloaded on 22 July 2013. The data we used was a superset of data used in the published TCGA head and neck cancer analysis \[[@CR23]\]. For our analyses, the TCGA HNSCC cohort consisted of 373 patient samples with HM450K data available. Only limited clinical annotation was available for these TCGA samples, thus only the variables of overall survival status and tumour-node-metastases (TNM) stage were used for downstream analyses. Patients with metastatic disease or those with an unknown M category (whereby the M category indicates the presence of metastatic disease) were excluded from further analysis, leaving a cohort of 331 TCGA HNSCC samples, which included 91 OTSCC. The samples used are listed according to anatomical subsite in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Additional file [2](#MOESM2){ref-type="media"} lists the downloaded TCGA sample IDs, the samples included for analysis and those also analysed in the TCGA head and neck cancer analysis \[[@CR23]\].

The data was grouped for interrogation in three ways. The first group consisted of 109 OTSCC samples processed in one batch from the Peter MacCallum Cancer Centre ("OTSCC cohort"). The second group combined the pre-processed OTSCC cohort with the 91 OTSCC samples from the TCGA database, which we termed the "combined OTSCC cohort". The final analysis was conducted on the "entire cohort" of samples, comprising 109 OTSCC and all 331 TCGA HNSCC samples (total *n* = 440).

Data analyses {#Sec4}
-------------

Bioinformatics processing of the raw IDAT files was performed utilising R statistical software (version 3.0.1, <http://cran.r-project.org/>). Currently, no consensus guidelines exist on the optimal method of pre-processing HM450K or the optimal method of feature selection. Given the variety of methods accounting for the same technical biases without clear indication of superiority between the techniques, for the pre-processing and subsequent downstream analyses described below, each method was considered of similar quality. The workflow for the bioinformatics analysis is summarised in Fig. [1](#Fig1){ref-type="fig"}, and the methods of analysis for each of the cohorts is summarised in Additional file [1](#MOESM1){ref-type="media"}: Table S2, according to the R software library packages utilised.Fig. 1Workflow for bioinformatics processing of raw data

Data pre-processing, filtering and normalisation of data {#Sec5}
--------------------------------------------------------

Due to the different pre-processing criteria and stringency criteria utilised according to each R package, different subgroups from each cohort were defined and were analysed separately. Details of the different criteria utilised according to each library is outlined in the "[Methods](#Sec11){ref-type="sec"}" section and in Additional file [1](#MOESM1){ref-type="media"}: Table S2. However, regardless of what pre-processing criteria were utilised, the size of the refined cohort examined or the combinations of cohorts analysed, results for the downstream analyses were similar.

Downstream processing and feature selection {#Sec6}
-------------------------------------------

### Unsupervised feature selection {#Sec7}

After quality control and pre-processing of 450K data using Minfi and Methylumi, 83/109 samples from the OTSCC cohort, 174 (83 OTSCC cohort plus 91 TCGA OTSCC) from the combined cohort and a total of 414 samples for the entire cohort were taken through to analysis. A bimodal distribution of *β* values for the OTSCC cohort and combined OTSCC cohort was observed indicating the absence of a group of samples with promoter hypermethylation (Fig. [2](#Fig2){ref-type="fig"}). Similarly, hierarchical clustering, multidimensional scaling (MDS) plots and principal components analysis did not clearly identify a subgroup of differentially methylated samples according to phenotypic data (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). These findings were again confirmed using another technique in RnBeads to look at the clustering of data, mean silhouette values. Figure [3](#Fig3){ref-type="fig"} demonstrates the poor classification of samples using this method and the numerous small clusters identifiable throughout the dataset, with little similarities between them. A silhouette value of "1" indicates good classification of the observation into the cluster, and a value of "0" indicates that the observation lies independent of the groupings, whilst a negative value indicates poor classification and likely incorrect grouping (<http://stat.ethz.ch/R-manual/R-devel/library/cluster/html/silhouette.html)> \[[@CR24]\]. Given that increasing the number of clusters makes the similarities within the cluster worse (approaches "0"), this suggests that the clustering of samples is based on very subtle and small differences in methylation.Fig. 2Plot of median beta values of the combined OTSCC cohort. A plot of the median beta values for the combined cohort of 174 OTSCC samples with outcome data, with the *blue line* indicating the overall median value for the group. A bimodal distribution is observed, without evidence of a hypermethylated group of samplesFig. 3Plot of the average silhouette value according to the number of clusters. This was assessed on RnBeads using an average linkage-based algorithm. The combined cohort demonstrates no distinct clustering according to observed methylation values. A silhouette value of "1" indicates good classification of the observation into the cluster, a value of "0" indicates that the observation lies independent of the groupings, whilst a negative value indicates poor classification and likely incorrect grouping

Therefore, despite increasing the OTSCC cohort size by inclusion of the 91 TCGA OTSCC samples to create a combined cohort of 174 OTSCC samples, DNA methylation data did not identify any unique subgroups according to phenotypic data. Investigating the entire cohort of 414 heterogeneous HNSCC samples also failed to demonstrate clear clustering of samples according to methylation profiles (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). This was not surprising as heterogeneous cohorts of head and neck samples are likely to demonstrate heterogeneous methylation profiles.

### Feature selection methods {#Sec8}

Utilising a variety of feature selection methods, we sought to determine if methylation was informative for patient survival or other clinicopathological variables.

For the OTSCC cohort, the relationship between DNA methylation and multiple phenotypic variables was investigated. This included assessment of relationship with overall survival, smoking history, history of alcohol excess and age \<45 years versus \>45 years due to the recognition of a subpopulation of younger patients that develop OTSCC in the absence of any risk factors \[[@CR25], [@CR26]\]. Of particular interest was to determine if tumours with nodal involvement had a differential methylation profile compared to those without, given that nodal status (N category) is one of the most reliable clinical risk classifiers of worse prognosis \[[@CR27]\]. Analyses investigating the relationship between DNA methylation and ECOG performance status, progression-free survival, disease-specific survival, T category, pathological differentiation status, and gender were also performed.

Based on the clinical annotation available for the TCGA cohort, the supervised analyses for the combined OTSCC cohort and the entire cohort only investigated the association between DNA methylation and overall survival status, and DNA methylation and TNM staging.

#### Linear models for microarray data analyses {#FPar1}

A linear models for microarray data (LIMMA) framework was initially utilised to interrogate the pre-processed OTSCC cohort (*n* = 83). After correction for multiple testing, significant associations between DNA methylation and gender, age and pathological differentiation status were identified (*q* values \<0.05, Benjamini-Hoechberg method). These specific variables were investigated further to see if they were informative for patient survival. Given the small numbers of samples in the age less than 45 years category (less than 10 samples), only methylation status according to gender and differentiation status were investigated for their impact on patient outcome.

For the analysis according to differentiation status, there were 25 patients with poorly differentiated tumours compared with 58 well differentiated tumours. Of these poorly differentiated tumours, 13 patients died. For the analysis according to gender, there were 57 male patients and 26 female patients, of which 27 male and 11 female patients survived. The LIMMA framework was used to discern if probes that significantly defined a variable were also associated with patient survival. However, no significant association between a tumour's differentiation status stratified according to differential methylation profiles, and patient survival was found (*q* value \>0.05). Similarly, no association was found when analysed according to patient gender (*q* value \>0.05).

When the combined OTSCC cohort (*n* = 174) was investigated with dmpFinder, after correction for multiple testing, methylation values were found to be uninformative for survival status and TNM stage. For overall survival, 28,078 probes had a *p* value of less than 0.05 but failed to reach significance (*q* value \>0.05) after correction for multiple testing. When disease stage was used as the classifier, 19,472 probes were identified with *p* values \<0.05, with one probe remaining after correction for multiple testing. This single probe within a promoter region corresponded to a SNP (cg17508434, a promoter-associated CpG to the LMTK2 gene). Please refer to the "[Methods](#Sec11){ref-type="sec"}" section for information regarding filtering of probes. In a separate analysis where filtering of SNP-associated probes were removed, no informative probes were identified.

Therefore, these analyses suggested that methylation values did not inform patient outcome. The small numbers of events as described may have impacted these findings.

#### Machine learning approaches {#FPar2}

Machine learning algorithms were also employed for analyses of the data. These were wrapped into a tool called "Genome toolbox" (GTB), a custom R library (personal communication Dr Justin Bedo, IBM) \[[@CR28], [@CR29]\]. Initially, the OTSCC cohort (*n* = 83) was assessed using centroid feature selection (CFS) with three-fold cross validation. A performance of 1.0 represents a 100 % chance of being able to classify groups according to the nominated variable, according to the number of methylation probes interrogated. A prediction performance of 0.5 represents a prediction capability no better than chance to classify the variable. Overall, prediction performance was poor and ranged between 0.5 to 0.7 for classification of pathological differentiation status, history of alcohol excess and smoking history according to DNA methylation. The prediction performance utilising other phenotypic variables was worse. The top eight ranked methylation probes identified to be informative for overall survival in the OTSCC cohort (cg141693, cg079784, cg148610, cg146787, cg184013, cg080496, cg137586, cg0322520) failed to classify samples according to survival status in the combined OTSCC cohort and the entire cohort. When the alternate method of recursive feature elimination -- support vector machine (RFE-SVM) was used, again no significant association between DNA methylation and survival status was identified.

A similar analysis was performed using machine learning methods for the larger combined OTSCC cohort (*n* = 174), using overall survival status as the classifying variable. For each method, ranges of tuning parameters (kernels and lambda values) were employed to optimise the prediction performance. However, both CFS and RFE-SVM models demonstrated no prediction capability, with performance ranging from 0.52 to 0.58 for both methods (whereby a prediction performance of 0.5 indicates no prediction capability beyond chance, Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Prediction performance plots for overall survival. **a** Prediction performance plot for overall survival of the combined oral tongue cohort of the mean value derived from the machine learning method RFE-SVM using a range of parameters (lambda range 0.01 with a poly kernel). *Error bars* represent the range of values obtained across the three-fold cross validation performed. The prediction performance ranged between 0.5 and 0.58 indicating a poor performance. **b** Representative prediction performance plot for overall survival of the combined oral tongue cohort using CFS. The training set demonstrates a decrease in performance with an increasing number of probes utilised, and the test model derived from the training set shows poor performance. *Error bars* represent the range of values across the three-fold cross validation performed. For both plots, a performance of 1.0 represents a 100 % chance of being able to classify groups according to the nominated variable, according to the number of probes interrogated. A prediction performance of 0.5 represents a capability of no better than chance

In addition, using these machine learning frameworks, a variety of other mathematical models were investigated including the *t* test and the LIMMA method. These analyses similarly demonstrated poor prediction performance metrics supportive of the conclusion that a prognostic methylation signature did not exist for the cohort.

Discussion {#Sec9}
==========

In a uniform cohort of samples from a single head and neck subsite, using both an agnostic approach to the data and a number of feature selection approaches, we were unable to identify a differentially methylated group of samples and we were unable to identify a methylation profile informative for clinicopathological features.

A number of previous reports have suggested the identification of prognostic signature for HNSCC, using a variety of approaches including high throughput methylation assessments \[[@CR8], [@CR11]--[@CR13], [@CR30]--[@CR32]\]. However, the cohorts examined were generally small, samples analysed were from heterogeneous head and neck subsites, and though some groups identified a hypermethylated group of samples and prognostically informative loci, none of these were reproducible between studies. Furthermore, some prognostically significant probes identified correspond to known SNPs \[[@CR8], [@CR11]\], which raises concerns regarding the reliability of these probes to assay DNA methylation. Our study of a large cohort of samples from a single subsite was unable to identify a hypermethylated group of samples or identify an informative methylation signature. Interestingly, the TCGA analyses of a heterogeneous group of 279 HNSCC samples that overlapped the samples we utilised (Additional file [2](#MOESM2){ref-type="media"}) identified four groups of tumours according to DNA methylation status, with a hypermethylated, hypomethylated, normal-like and CpG island methylated group of samples \[[@CR23]\]. However, the association between methylation group and survival status was not significant (\[[@CR23]\], Supplementary Figure S1.5b, *p* = 0.05).

Technical issues relating to the HM450K platform itself may have impaired the identification of a methylation profile. The use of formalin-fixed paraffin-embedded (FFPE)-derived DNA for the OTSCC cohort may have affected findings by affecting the quality of reported methylation or the number of CpG sites assessed. In part, this was accounted for by the use of different stringency filtering criteria. In recognition of the fact that an allelic state (SNP) may be informative for the methylation status of particular loci and may correlate with disease states \[[@CR33], [@CR34]\], analyses were performed that included and excluded all SNP probes. However, no differences in results were observed. Perhaps the most significant limitation of the HM450K array is that it only interrogates \~2 % of CpGs within the human genome, and thus informative regions may be missed. At present, there are a limited number of whole genome bisulfite sequencing studies, with only one cancer-related study published which investigated a single colorectal cancer sample \[[@CR35]\]. Our findings may also have been limited by the sample size of the cohort. However, this study represents one of the largest of its kind that examines a single head and neck subsite with high throughput methodology.

We tested whether observed methylation in isolation served as a prognostic marker or whether it correlated with any clinicopathological feature. However, the clinical impact of altered methylation is likely to be influenced by other factors that this approach does not account for. These other factors include whether the quantity of detected methylation is relevant, the location of informative CpG sites, and the known complex interactions between DNA methylation and other genetic and epigenetic factors, particularly those regulated by the polycomb repressor group proteins \[[@CR5], [@CR36], [@CR37]\].

The relationship between DNA methylation and gene expression is complex, given the absence of a uniform effect of the presence of methylation. This impacts the findings of correlative analyses. Different threshold quantities of methylation has been found to differentially impact gene expression according to CpG location and tissue histotype in a study by Liu et al. which examined 992 different tumour samples from the TCGA project assessed by high throughput methylation analyses \[[@CR38]\]. Similarly, though the functional impact of hypermethylation of CGIs in promoter regions is best understood and is thought to usually correlate with gene repression \[[@CR5]\], the location of informative CpG sites is not comprehensively known. Increasingly, research demonstrates that methylation outside promoter regions is also informative and that the presence of methylation does not always correlate with gene repression \[[@CR39]\]. Similarly, long-range epigenetic activation (LREA) and long-range epigenetic silencing (LRES) needs to be considered, which refers to the regional activation or silencing of often very large domains that can be mediated by DNA hypermethylation \[[@CR35], [@CR40]\]. LRES and LREA may result in the differential expression of genes, through the induction of a DNA conformational change enlisting the use of alternate transcription start sites or through the inhibition of transcription repression factors, similar to that seen with the CTCF insulator proteins \[[@CR39]--[@CR41]\]. Lastly, an analysis of the clinical significance of methylation in isolation ignores the complex interplay between the genome and epigenome. This is easily demonstrated through the known significant clinical impact of the CIMP-high phenotype in colorectal cancer and the simultaneous presence of *TP53* mutations and *BRAFV600E* mutations or, similarly, the G-CIMP subgroup of glioma tumours with concurrent *IDH1* mutations \[[@CR6], [@CR7]\]. Indeed, the TCGA analysis of 279 heterogeneous HNSCC identified a significant relationship between hypomethylation and the loss of function mutation of *NSD1*, but the impact on patient outcome was not reported \[[@CR23]\]. The interaction between DNA methylation and other epigenetic modifiers, such as histone modifications, is also complicated by a possible bivalent state of gene transcription, where both active marks such as acetylation (e.g. H3K9ac), and repressive marks such as H3K27me3, can associate with DNA methylation \[[@CR5], [@CR37], [@CR40], [@CR42]\]. This indicates that the presence of DNA methylation is not necessarily representative of a binary effect on gene expression and thus its correlation with clinicopathological features.

Our analysis sought to determine whether methylation in isolation heralded any prognostic information for OTSCC patients, and to some extent, the approach did account for some of the more complex issues discussed. The agnostic analyses with the unsupervised feature selection avoided assumptions made on the significance of *β* values, the location of informative probes or even the resultant impact of altered methylation. However, it may be that methylated regions defined according to the effect on gene expression may need to be identified before reliable clinical correlations will be observed.

Conclusions {#Sec10}
===========

The detailed assessment of the methylation status of over 450,000 CpG sites with the HM450K array in a comprehensively annotated OTSCC cohort importantly demonstrated that a methylation signature or prognostically informative CpG sites could not be found. The presence of DNA methylation could not stratify clinicopathological variables according to impact on patient outcome. Although a number of technical factors have been discussed, the absence of an independent prognostic methylation profile likely results from the complex and dynamic interaction of DNA methylation with other genomic and epigenomic mechanisms of gene regulation. Whole genome bisulfite sequencing in combination with other "omic" profiling may provide additional information regarding the biological impact of methylation. However, within the limitations of our current understanding, the use of FFPE-derived DNA, and the size of the cohort examined, our findings suggest that methylation alone is unlikely to inform patient outcome for OTSCC.

Methods {#Sec11}
=======

Preparation of bisulfite-modified DNA {#Sec12}
-------------------------------------

DNA extraction and bisulfite modification has been previously described \[[@CR15], [@CR22]\]. One microgram of DNA was bisulfite modified (BS) and eluted twice, into a total volume of 100 μL. DNA precipitation was utilised to prepare the BS DNA for a final volume of 7 μL resuspended in TE buffer for processing on the HM450K array. DNA quality post bisulfite modification and precipitation was confirmed by checking the known *CDKN2A* methylation status by MS-HRM on selected samples.

Methylation analysis {#Sec13}
--------------------

Samples were sent to the Australian Genome Research Facility (AGRF, Melbourne, Australia) for processing on the HM450K array as a single batch. Methodology for the analysis has been previously published \[[@CR43], [@CR44]\]. Raw IDAT files of the data generated were provided to us by AGRF. Data from samples passing initial quality filtering have been deposited in GEO (Gene Expression Ominibus) GSE79556.

Bioinformatics analysis {#Sec14}
-----------------------

Given the absence of consensus on processing of high throughput methylation data, we chose to approach the data as comprehensively as possible with different software libraries and packages (Additional file [1](#MOESM1){ref-type="media"}: Table S2). The aim of this approach was to internally validate findings with orthogonal methodology or similar methodology but also to optimise opportunity for identifying significant correlations. Separate analyses were performed using each package to pre-process data, and for each refined cohort, downstream analyses were performed as described below.

Bioinformatics processing of the raw IDAT files was performed utilising R statistical software (version 3.0.1, <http://cran.r-project.org/>). Software library packages used included Methylumi version 2.6.1 (<http://www.bioconductor.org/packages/release/bioc/html/methylumi.html>), Minfi version 1.6.0 (<http://www.bioconductor.org/packages/2.12/bioc/html/minfi.html>), ChAMP version 0.99.0 (<http://www.bioconductor.org/packages/2.13/bioc/html/ChAMP.html>) \[[@CR45]\], wateRmelon version 1.0.3 (<http://www.bioconductor.org/packages/2.13/bioc/html/wateRmelon.html>) \[[@CR46]\], RnBeads version 0.99.9 (<http://rnbeads.mpi-inf.mpg.de/>) and a custom machine learning package (GTB version 0.0.1) \[[@CR28], [@CR29]\] (personal communication Dr Justin Bedo, IBM).

Pre-processing of data {#Sec15}
----------------------

We performed standard quality control assessments in-built into the library packages utilised. The raw data initially underwent quality control assessment through inspection of the *β* value distribution plots, for the identification of outlying samples. Detection *p* values were then used to identify failed probes defined as those that did not emit a signal above background levels \[[@CR45], [@CR46]\]. In addition, two further quality assurance measures were performed prior to downstream analysis; Firstly, our data was found to be comparable and did not lie outside of other HM450K datasets, by analysis of the cohort with 8654 publically available samples curated on Marmal-aid (<http://marmal-aid.org/>, version 1.1.1) \[[@CR47]\] (Additional file [3](#MOESM3){ref-type="media"}). Secondly, a number of samples were also processed and analysed in replicate on the HM450K array by AGRF, which confirmed the reproducibility of results (data not shown). We have previously published results from this cohort that compared the methylation analyses of specific loci utilising four orthogonal methodologies (HM450K array, SMART-MSP, pyrosequencing and MS-HRM) with the TCGA HNSCC dataset, which confirmed the reproducibility and robustness our data \[[@CR15]\].

Filtering of the data {#Sec16}
---------------------

As there is no consensus on which probes should be removed from downstream analysis, a variety of filtering criteria was used to account for the issues described further (summarised on Additional file [1](#MOESM1){ref-type="media"}: Table S2), thereby refining different sized cohorts. Despite the different sizes of the cohorts refined from the use of different criteria, including and excluding SNPs, overall, downstream analyses for these different cohorts created by the use of different filtering and normalisation methods were similar. Factors accounted for in our approach to the filtering of data are described further below.

The HM450K was initially reported to include 3091 probes interrogating non-CpG sites (context specific probes), and 65 single nucleotide polymorphisms (SNPs) \[[@CR20]\]. However, in addition to these, it is recognised that confounding of results may be introduced by the following: an additional (unreported) 66,877 SNP probes, at or in very close proximity to the interrogated CpG site; by the sex chromosome probes; by consistently poor performing probes; and by co-localising (off-target mapping) probes \[[@CR48]--[@CR52]\]. Whilst most studies have determined the number of confounding probes using in silico methods, when HM450K data was compared with data generated by whole genome bisulfite sequencing, up to approximately 200,000 probes were found to introduce artefactual methylation assessments and require consideration of removal prior to downstream processing \[[@CR52]\]. The sex chromosome probes introduce bias as X-inactivation is regulated by hypermethylation, and the copy number of X-chromosomes varies according to gender \[[@CR49]\]. This is additionally relevant for autosomal probes that hybridise to the sex chromosomes. Some probes reporting high intensity *β* values are noted to be unreliable on repeated analyses, whereby methylation values are unable to be replicated by alternative method \[[@CR48]\]. In addition, up to 9 % (\~42,000) probes are reported to co-localise to alternative sites due to homologous sequences elsewhere, such as pseudogenes \[[@CR50]\]. Dependent on the choice of alignment stringency (for example, the number of mismatches permitted), one study determined that up to 29 % (\~140,000) probes misaligned when two mismatches were permitted \[[@CR51]\]. Probes interrogating SNPs may introduce artefactual methylation measurements dependent on the genotype of the patient and the frequency of the polymorphism in the population. Furthermore, SNPs may also interfere with probe hybridisation dynamics if a SNP exists within the probe target sequence. This may alter the observed methylation measurements from the true extent of methylation at these sites \[[@CR48], [@CR49]\]. However, specific allelic states (SNPs) are recognised to be significantly associated with the methylation status of certain genes \[[@CR33], [@CR34]\], which argues that it may be crucial to include SNP probes in downstream processing.

Data normalisation {#Sec17}
------------------

Background fluorescence correction was achieved through methods available through Methylumi and by utilising the normal exponential using out-of-band probes (NOOB) method. Data normalisation was also performed to account for the significant technical biases that result from the use of different chemistry underlying the two probes on the HM450K array, with the Infinium II probes demonstrating a smaller dynamic range with less sensitivity for methylation values at extreme ranges and inferior reproducibility of methylation values with repeated testing \[[@CR53]\]. These biases were accounted for within the analysis using the subset-quantile normalisation (SQN) methods available through Methylumi and Minfi packages \[[@CR54]\], subset-quantile within array normalisation (SWAN) \[[@CR44]\], and beta mixture quantile dilation (BMIQ) \[[@CR55], [@CR56]\].

Batch variation was corrected using the singular value decomposition (SVD) method \[[@CR57]\], and the ComBat method \[[@CR58]\] available on the ChAMP library. A customised method of pre-processing the data was also performed using the wateRmelon package, using the "dasen" method of normalisation of β-intensities of each probe type \[[@CR46]\].

Downstream processing and feature selection {#Sec18}
-------------------------------------------

For the agnostic interrogation of data, unsupervised feature selection was performed using multidimensional scaling (MDS) plots, hierarchical clustering, and principal components analysis. Two main supervised feature selection approaches were used to identify differential methylation. Firstly, a linear models for microarray data (LIMMA) approach was used, through "dmpFinder" (differentially methylated probe Finder) with false discovery rates (FDR) of a *p* value less than 0.05 \[[@CR59], [@CR60]\]. RnBeads also hosts a method of assessing methylation according to specified regions (compared to a single probe). Secondly, machine learning methods were also used which were based on a recursive feature elimination (RFE) framework and incorporated recursive feature elimination -- support vector machine (RFE-SVM), as well as centroid feature selection (CFS). Both methods used a three-fold cross validation \[[@CR28]\]. The machine learning approach to supervised feature selection is an empirical method to analyse the data in its entirety, where training and learning models to select a nominated feature are generated by cross validation within the dataset.

Abbreviations {#Sec19}
=============

BMIQ, beta mixture quantile dilation; BS, bisulfite modified; CFS, centroid feature selection; ComBat, correction for batch effect; dmpFinder, differentially methylated probe finder; ECOG, Eastern Cooperative Oncology Group; HNSCC, head and neck squamous cell carcinomas; LIMMA, linear models for microarray data; MDS, multi-dimensional scaling; NOOB, normal-exponential using out-of-band probes; OTSCC, oral tongue squamous cell carcinomas; RFE-SVM, recursive feature elimination -- support vector machine; SNPs, single nucleotide polymorphisms; SQN, subset-quantile normalisation; SVD, singular value decomposition; SWAN, subset-quantile within array normalisation; TCGA, The Cancer Genome Atlas; TNM, tumour-node-metastases.
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